The Complete Guide to Oncology Board Review in 2026

Why Oncology Board Review Feels Overwhelming — and How to Fix It

For most hematology-oncology fellows, the prospect of the ABIM board examination arrives at the worst possible time: the final stretch of fellowship, when clinical responsibilities are at their peak and study time is at its thinnest. The content domain is vast — hematologic malignancies, solid tumors, supportive care, palliative medicine, clinical trial methodology — and the stakes could not be higher.

Yet every year, physicians who approach the exam strategically pass on the first attempt, often with months to spare in terms of their study timeline. The difference is rarely raw intelligence. It is almost always method.

This guide covers everything you need: the structure of the ABIM hematology-oncology boards, the highest-yield topic areas, a realistic study timeline, and why adaptive AI-powered question banks are becoming the gold standard for oncology board review in 2026.

Understanding the ABIM Hematology-Oncology Board Examination

The ABIM certifying examination in hematology-oncology is a computer-based, single-day exam administered at Prometric test centers. Key logistics to know:

• Format: Multiple-choice questions (MCQs), primarily single best-answer format
• Length: Approximately 200 questions over one day, divided into timed blocks
• Content blueprint: Published by ABIM and updated periodically — always download the current version before you begin prep
• Passing score: ABIM uses a scaled scoring method; the pass/fail cut is not publicly disclosed but is criterion-referenced, not norm-referenced
• Eligibility: Completion of an ACGME-accredited hematology-oncology fellowship; passing ABIM internal medicine certification

The blueprint allocates content across hematologic malignancies (≈ 40%), solid tumors (≈ 35%), benign hematology (≈ 15%), and cross-cutting themes such as palliative care, clinical pharmacology, and research methods (≈ 10%). These proportions shift slightly with each exam cycle, so treat them as estimates.

The 8 Highest-Yield Topic Areas for Oncology Board Review

Based on the ABIM blueprint and the experience of fellows who have sat the exam, the following areas consistently yield the highest return on study time:

1. Acute Myeloid Leukemia (AML)

AML is arguably the single most tested topic in hematologic malignancy. Examiners test induction regimens (7+3 cytarabine/anthracycline vs. CPX-351 for secondary AML), risk stratification using ELN 2022 criteria, targeted agents (FLT3 inhibitors, IDH1/IDH2 inhibitors, venetoclax combinations), and transplant decision-making. Know your molecular mutations cold.

2. Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL questions probe R-CHOP vs. R-CHOP + polatuzumab in frontline treatment, the role of interim PET/CT, salvage regimens for relapsed/refractory disease (R-ICE, R-DHAP, CAR-T eligibility), and the distinction between GCB and non-GCB subtypes and their prognostic implications.

3. Multiple Myeloma

The myeloma landscape has expanded rapidly. Boards test transplant eligibility criteria, VRd vs. daratumumab-based induction, maintenance with lenalidomide, and the evolving role of BCMA-directed therapies (belantamab, CAR-T, bispecifics). IMWG response criteria and relapse definitions are frequently tested.

4. Breast Cancer

Breast cancer is the top solid tumor on the exam. Focus on receptor-driven treatment algorithms (HR+/HER2−, HER2+, triple-negative), CDK 4/6 inhibitors and their resistance mechanisms, neoadjuvant chemotherapy indications, trastuzumab deruxtecan, pembrolizumab + chemotherapy for TNBC, and BRCA testing implications.

5. Lung Cancer (NSCLC)

Molecular profiling is the crux of NSCLC questions. Know actionable alterations (EGFR, ALK, ROS1, KRAS G12C, MET exon 14, NTRK, RET, BRAF V600E), their matching targeted therapies, and the role of immunotherapy (PD-L1 expression thresholds, combination approaches). Small cell staging and platinum/etoposide + atezolizumab rounds out the lung section.

6. Colorectal Cancer

Staging and resectability, MSI-H/dMMR testing for immunotherapy eligibility, KRAS/NRAS/BRAF testing, FOLFOX vs. FOLFIRI, bevacizumab vs. cetuximab selection, and hepatic metastasis management are all high-yield.

7. Chronic Lymphocytic Leukemia (CLL)

Treatment indications, BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), venetoclax + obinutuzumab combinations, del(17p)/TP53 mutation impact on management, and Richter transformation are the CLL cornerstones.

8. Benign Hematology

Often underestimated, benign hematology covers coagulopathies, TTP/HUS (ADAMTS13, plasma exchange), immune thrombocytopenia (ITP), hemolytic anemias, hemoglobinopathies, and transfusion medicine. These questions reward systematic clinical reasoning over memorization.

A Realistic 6-Month Study Timeline

Most fellows begin serious board prep 4–6 months before their exam date. Here is a framework that has worked consistently:

• Months 1–2: Complete a first pass through all hematologic malignancies. Do 20–30 MCQs per day. Review every wrong answer and every explanation — even when you got the question right.
• Months 3–4: Shift to solid tumors. Continue daily MCQ practice. Begin tracking your performance by topic to identify weak areas.
• Month 5: Deep dive into your identified weak areas. Revisit the ABIM blueprint and confirm coverage. Start simulating exam conditions with timed practice blocks.
• Month 6: Full-length practice exams, rapid review of high-yield summaries, and light maintenance practice. Protect your sleep in the final two weeks.

Why AI-Powered Question Banks Are Changing Oncology Board Prep

Traditional question banks — static PDFs, fixed printed questions, or outdated software — have two fundamental problems for the modern oncology fellow. First, the treatment landscape in oncology moves faster than any printed resource can keep pace with. Second, static questions are eventually memorized rather than learned.

AI-powered platforms like MeducationAI address both problems. By generating question variants from the same underlying concept, the system prevents rote answer memorization and tests your ability to apply reasoning to novel clinical presentations — exactly what the ABIM exam requires. Questions are continuously updated as guidelines change, and adaptive algorithms prioritize the topics where your performance data shows the greatest gaps.

Key Takeaways

• The ABIM hematology-oncology exam tests clinical reasoning, not memorization — your study method must match that
• The 8 highest-yield topics are AML, DLBCL, myeloma, breast cancer, NSCLC, colorectal cancer, CLL, and benign hematology
• A 6-month plan with daily MCQ practice and systematic weak-area review is achievable alongside fellowship demands
• AI-generated question variants and adaptive learning are now the most efficient way to prepare

References

• ABIM Hematology-Oncology Certification Exam Blueprint — abim.org
• Döhner H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations. Blood. 2022;140(12):1345–1377.
• NCCN Clinical Practice Guidelines in Oncology — nccn.org
• Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. NEJM. 2021;384(9):842–858.